| Barbra S Morykwas, AUD | |
|
6802 S Olympia Ave Ste 200, Tulsa, OK 74132-1826 | |
| (918) 388-9090 | |
| (918) 388-9741 |
| Full Name | Barbra S Morykwas |
|---|---|
| Gender | Female |
| Speciality | Audiologist |
| Location | 6802 S Olympia Ave Ste 200, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154614899 | NPI | - | NPPES |
| 200334170A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 3590 (Oklahoma) | Primary |
| Provider Name | Ear, Nose & Throat Specialists Of Tulsa, Llp |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1093873168 PECOS PAC ID: 5991764094 Enrollment ID: O20041005000764 |
News Archive
In a letter dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, "has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled," denying "the agenda was crafted to achieve a predetermined outcome," the Canadian Press/Winnipeg Free Press writes.
Preliminary data from one of the first clinical trials to test a stem cell-targeting drug in cancer patients shows that while the drug did not prolong survival, its suppressing effect on patients' stem cells was impressive enough to send investigators looking for a better drug to try.
The Vascular Disease Foundation (VDF) presented its annual awards at the organization's seventh annual meeting in Alexandria, VA. The awards honor the work of citizens, health care providers, organizations, researchers and companies that have enhanced the understanding and/or treatment of peripheral vascular diseases.
Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
› Verified 6 days ago
| Provider Name | Audiology Doctors Of Tulsa Pllc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1518148550 PECOS PAC ID: 2860566478 Enrollment ID: O20080730000804 |
News Archive
In a letter dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, "has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled," denying "the agenda was crafted to achieve a predetermined outcome," the Canadian Press/Winnipeg Free Press writes.
Preliminary data from one of the first clinical trials to test a stem cell-targeting drug in cancer patients shows that while the drug did not prolong survival, its suppressing effect on patients' stem cells was impressive enough to send investigators looking for a better drug to try.
The Vascular Disease Foundation (VDF) presented its annual awards at the organization's seventh annual meeting in Alexandria, VA. The awards honor the work of citizens, health care providers, organizations, researchers and companies that have enhanced the understanding and/or treatment of peripheral vascular diseases.
Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Barbra S Morykwas, AUD 6802 S Olympia Ave Ste 200, Tulsa, OK 74132-1826 Ph: (918) 388-9090 | Barbra S Morykwas, AUD 6802 S Olympia Ave Ste 200, Tulsa, OK 74132-1826 Ph: (918) 388-9090 |
News Archive
In a letter dated April 25, Amy Patterson, associate director for science policy in the office of the director of the National Institutes of Health, "has refuted criticism of the way a meeting held to allow a biosecurity advisory group to review controversial bird flu studies was handled," denying "the agenda was crafted to achieve a predetermined outcome," the Canadian Press/Winnipeg Free Press writes.
Preliminary data from one of the first clinical trials to test a stem cell-targeting drug in cancer patients shows that while the drug did not prolong survival, its suppressing effect on patients' stem cells was impressive enough to send investigators looking for a better drug to try.
The Vascular Disease Foundation (VDF) presented its annual awards at the organization's seventh annual meeting in Alexandria, VA. The awards honor the work of citizens, health care providers, organizations, researchers and companies that have enhanced the understanding and/or treatment of peripheral vascular diseases.
Epizyme, Inc., a company leading the discovery and development of first-in-class, targeted cancer therapeutics against epigenetic targets, announced today the publication of two new review papers in the area of epigenetics. Together, the articles provide an overview of the major epigenetic enzyme classes, as well as chemical biology approaches for discovering small molecule inhibitors of these epigenetic enzymes, and demonstrate Epizyme's scientific leadership in the area of epigenetics.
Caprion - HistoGeneX announced today that the company is launching a molecular PCR testing service for identifying patients with COVID-19.
› Verified 6 days ago
Allison P Finch, M.S.,CCC-A Audiologist Medicare: Accepting Medicare Assignments Practice Location: 6802 S Olympia Ave Ste 200, Tulsa, OK 74132 Phone: 918-388-9740 Fax: 918-388-9741 | |
Jensen James, AU.D. Audiologist Medicare: Medicare Enrolled Practice Location: 5350 E 31st St Ste 301, Tulsa, OK 74135 Phone: 918-392-7600 Fax: 405-548-4349 | |
Audiology Of Tulsa Inc Audiologist Medicare: Not Enrolled in Medicare Practice Location: 4564 S Harvard Ave, Ste A, Tulsa, OK 74135 Phone: 918-745-9052 Fax: 918-749-9770 | |
Erin Buchanan, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 6475 S Yale Ave Ste 401, Tulsa, OK 74136 Phone: 918-502-9555 Fax: 918-502-9559 | |
Karen Fernow, AU.D Audiologist Medicare: Accepting Medicare Assignments Practice Location: 3105 S Harvard Ave, Tulsa, OK 74135 Phone: 918-508-7601 Fax: 918-508-7603 | |
Grace Holderman, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 5350 E 31st St Ste 301, Tulsa, OK 74135 Phone: 918-392-7600 Fax: 405-548-4350 | |
Ms. Julia A Shirk, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1145 S Utica Ave, Suite 302, Tulsa, OK 74104 Phone: 918-592-3737 Fax: 918-592-3337 |